Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Bevacizumab for Brain Metastases
NCT02681549Phase 2Completed
- Sponsor
- Yale University
- Start
- May 2016
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in melanoma and non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Yale University. Primary endpoint: Brain Metastasis Response Rate at 2 years. Started May 2016; status: completed.
02
Drugs
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02681549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681549.